Kisqali & Truqap now subsidised by PBS
The drug Kisqali (ribociclib), which was previously available for advanced cases, is now being subsidised for a broader group of patients, specifically those with early-stage, hormone receptor-positive, HER2-negative, lymph node-positive breast cancer who are at high risk of their cancer returning after surgery .... now available on PBS ...... This is not only a huge saving on costs - but it will hopefully prevent some women with early stage BC from a recurrence or progression. Read more about it here: https://7news.com.au/news/life-saving-breast-cancer-drug-now-cheaper-thanks-to-a-expansion-of-the-pharmaceutical-benefits-scheme-c-19213732 It will definitely be on Channel 7 news tonight - probably other channels too. Another announcement today is: Thousands of other Australians will pay considerably less for breast cancer treatment due to a new federal government decision. Health Minister Mark Butler has announced that Truqap, a breast cancer drug, will be on the Pharmaceutical Benefits Scheme (PBS) from Wednesday, 1 October, with the start of Breast Cancer Awareness Month. Being on PBS means the treatment will be on the government-subsidised list of medicines. Truqap is used to treat breast cancer that is either locally advanced or metastatic and cannot be removed through surgery. Without the subsidy, patients were facing costs of $100,000 for a course of treatment on Truqap. From Wednesday, they will pay a maximum of $31.60 per script. https://www.sbs.com.au/news/article/breast-cancer-patients-to-save-thousands-as-new-drug-added-to-pbs/udwi5kklx